{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:09:23Z","timestamp":1788930563709,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick - borne zoonotic infectious disease. Severe SFTS cases exhibit an extremely high fatality rate, but there remain no effective clinical treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Propensity Score Matching (PSM) and logistic regression analysis were used to assess the efficacy, safety, and baseline factors influencing patient prognosis of tocilizumab in the treatment of SFTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 833 SFTS cases were included, of whom 171 received tocilizumab. After PSM, a higher recovery rate was observed in the tocilizumab group than in the control group (76.61% vs 67.70%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.039). However, the between-group difference in in-hospital mortality did not reach statistical significance after matching (16.96% vs 15.22%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.322). Regarding selected adverse events (AEs) such as co-infection, the between-group differences did not reach statistical significance; these represent observed differences in retrospectively recorded data and should not be interpreted as evidence of safety. Multivariable logistic regression showed that age \u2265 65 years, vasopressor therapy, platelet transfusion, and Ct value were associated with prognosis among tocilizumab-treated patients, with vasopressor use and platelet transfusion likely reflecting disease severity rather than independent causal determinants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective cohort, after PSM, tocilizumab use was associated with a higher recovery rate in SFTS patients, although the between-group difference in in-hospital mortality did not reach statistical significance. Observed differences in selected AEs were based on retrospectively recorded data and should not be interpreted as evidence of safety. Given the exploratory nature, prospective studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1894849","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:43:43Z","timestamp":1788929023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Quanman","family":"Hu","sequence":"first","affiliation":[{"name":"College of Public Health, Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehan","family":"Jin","sequence":"additional","affiliation":[{"name":"College of Public Health, Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Wei","sequence":"additional","affiliation":[{"name":"Huaiyang Disease Control and Prevention Center","place":["Zhoukou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundong","family":"Chen","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center","place":["Xinyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center","place":["Xinyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center","place":["Xinyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center","place":["Xinyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiyin","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Public Health, Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcai","family":"Duan","sequence":"additional","affiliation":[{"name":"College of Public Health, Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","first-page":"385","article-title":"Expert consensus on diagnosis and treatment of severe fever with thrombocytopenia syndrome","volume":"35","author":"Chen","year":"2022","journal-title":"Inf. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1419015","article-title":"The use of glucocorticoid in severe fever with thrombocytopenia syndrome: a retrospective cohort study","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.cmi.2025.02.004","article-title":"Development and validation of a novel mortality risk stratification simplified scoring scale for severe fever with thrombocytopenia syndrome","volume":"31","author":"Chen","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jinf.2014.08.001","article-title":"Severe fever with thrombocytopenia syndrome bunyavirus-related human encephalitis","volume":"70","author":"Cui","year":"2015","journal-title":"J. Infect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106181","article-title":"Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: a randomized clinical trial","volume":"89","author":"Ge","year":"2024","journal-title":"J. Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1002\/jmv.28093","article-title":"Coinfections in hospitalized patients with severe fever with thrombocytopenia syndrome: a retrospective study","volume":"94","author":"Ge","year":"2022","journal-title":"J. Med. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33611","article-title":"Viral shedding pattern of severe fever with thrombocytopenia syndrome virus in severely ill patients: a prospective, multicenter cohort study","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1693567","article-title":"Pathogen profile of co-infections and mortality determinants among patients with severe fever with thrombocytopenia syndrome","volume":"15","author":"Hu","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28894","article-title":"Fatal outcome of severe fever with thrombocytopenia syndrome (Sfts) and severe and critical Covid-19 is associated with the hyperproduction of Il-10 and Il-6 and the low production of Tgf-B","volume":"95","author":"Kang","year":"2023","journal-title":"J. Med. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-021-00541-3","article-title":"Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome","volume":"6","author":"Li","year":"2021","journal-title":"Signal. Transduct Target Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/s1473-3099(18)30293-7","article-title":"Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study","volume":"18","author":"Li","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118039","article-title":"Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3855\/jidc.19939","article-title":"Serum Il-6 and Il-10 levels are associated with fatal outcomes in patients with Sfts in China","volume":"19","author":"Liu","year":"2025","journal-title":"J. Infect. Dev. Ctries"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both Mil-6r and Sil-6r, but not by the receptors of other members of Il-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/shk.0000000000001527","article-title":"Analysis of severe fever with thrombocytopenia syndrome in critical ill patients in Central China","volume":"54","author":"Nie","year":"2020","journal-title":"Shock"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2388","article-title":"Efficacy of tocilizumab in the treatment of Covid-19: an umbrella review","volume":"32","author":"Rezaei Tolzali","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/v16121906","article-title":"Analysis of changes in viral load and inflammatory cytokines, as well as the occurrence of secondary infections, in Sfts patients treated with specific treatments: a prospective multicenter cohort study","volume":"16","author":"Seo","year":"2024","journal-title":"Viruses"},{"key":"B21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of Il-6 antagonists and mortality among patients hospitalized for Covid-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12985-024-02403-0","article-title":"Cytokines and lymphocyte subsets are associated with disease severity of severe fever with thrombocytopenia syndrome","volume":"21","author":"Song","year":"2024","journal-title":"Virol. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3892\/ijmm.2025.5610","article-title":"Current status of severe fever with thrombocytopenia syndrome in China","volume":"56","author":"Sun","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10238-013-0259-0","article-title":"Detection and evaluation of immunofunction of patients with severe fever with thrombocytopenia syndrome","volume":"14","author":"Sun","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/infdis\/jis452","article-title":"Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome","volume":"206","author":"Sun","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/infdis\/jit603","article-title":"The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan","volume":"209","author":"Takahashi","year":"2014","journal-title":"J. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711847","article-title":"Il-6 and Il-10 levels, rather than viral load and neutralizing antibody titers, determine the fate of patients with severe fever with thrombocytopenia syndrome virus infection in South Korea","volume":"12","author":"Yoo","year":"2021","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3349\/ymj.2024.0209","article-title":"Tocilizumab for patients with severe fever with thrombocytopenia syndrome: Tocilizumab observational Sfts study-1","volume":"66","author":"Yoo","year":"2025","journal-title":"Yonsei Med. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijid.2022.06.058","article-title":"Tocilizumab therapy for Il-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome","volume":"122","author":"Yoo","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3201\/eid2008.131857","article-title":"Severe fever with thrombocytopenia syndrome virus in ticks collected from humans, South Korea, 2013","volume":"20","author":"Yun","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104807","article-title":"Clinical efficacy of immunoglobulin on the treatment of severe fever with thrombocytopenia syndrome: a retrospective cohort study","volume":"96","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/cid\/cir804","article-title":"Hemorrhagic fever caused by a novel bunyavirus in China: pathogenesis and correlates of fatal outcome","volume":"54","author":"Zhang","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/jmv.26544","article-title":"Severe fever with thrombocytopenia syndrome in Hefei: clinical features, risk factors, and ribavirin therapeutic efficacy","volume":"93","author":"Zhang","year":"2021","journal-title":"J. Med. Virol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28712","article-title":"Pulmonary infection in patients with severe fever with thrombocytopenia syndrome: a multicentre observational study","volume":"95","author":"Zuo","year":"2023","journal-title":"J. Med. Virol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1894849\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:43:48Z","timestamp":1788929028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1894849\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":35,"alternative-id":["10.3389\/fcimb.2026.1894849"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1894849","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1894849"}}